Article Text

Download PDFPDF

4CPS-060 Effectiveness and economic analysis of weight-based versus fixed dosing of pembrolizumab in non -mall cell lung cancer
  1. J Ibanez-Caturla1,
  2. P Torrano-Belmonte1,
  3. L Fructuoso-González1,
  4. JA Gutiérrez Sánchez1,
  5. P Pacheco López2,
  6. MÁ Carvajal Sánchez1,
  7. M Guillén Díaz1,
  8. A Martínez Orea1,
  9. J León Villar1,
  10. JC Titos Arcos1
  1. 1Hospital Morales Meseguer, Pharmacy Service, Murcia, Spain
  2. 2Hospital Rafael Mendez, Pharmacy Service, Lorca, Spain


Background and Importance Pembrolizumab is an anti-PDL-1 monoclonal antibody widely used in a variety of tumoural diseases. Initially used in a fixed-dose regime, trials showed that a weight-based dosing was more cost-effective and thus it was authorised by the Pharmacy Committee in our centre.

Aim and Objectives To compare the effectiveness of pembrolizumab, either as a fixed 200 mg dose or as a weight based 2 mg/kg dose every three weeks, in combination with pemetrexed and platinum, used in the first line setting as treatment of non-squamous non-small-cell lung cancer (NSCLC), with a CPS count <50%. In addition, to evaluate the economic impact of this dosing change.

Material and Methods Retrospective, observational, descriptive study of all patients treated with pembrolizumab, pemetrexed and platinum in non-squamous NSCLC between January 2018-August 2022. Collected variables: age, sex, weight, dosing, number of cycles, best response, progresion-free survival (PFS), overall survival (OS). Actual cost was calculated accounting for each patient, cycle and milligram of pembrolizumab administered.

Results Forty-six patients (38 men and 8 women), with a median of 65 years old (range 39-77) were included. 26 patients (57%) received a weight based, 2 mg/kg dose (WD group). The median body weight was 73 kg in both groups (range 49-105). Overall response rate (complete/partial response) was 60% in the WD and 50% in the FD group. PFS was 13.24 months (CI95% 10-16.5) on average in the WD group and 13.7 months (CI95% 8.1-19.1) in the FD group. OS was 18.15 months (CI95% 14.3-22) in the WD group and 18.16 (CI95% 12.6-23.6) in the FD group. No significant differences were found in the log-rank test.

Patients in the WD group received an average of 148 ± 27 mg of pembrolizumab for a median of 22 cycles; the FD group received 200 mg and a median of 41 cycles. Most patients (95%) received a lower dose than those in the FD group. On average, the total treatment cost per patient was reduced by 34% in the WD group. The estimated saved public expenditure was €420852 in this pathology.

Conclusion and Relevance Pembrolizumab weight-based dosing was as effective as the fixed dose regime and reduced costs in patients with NSCLC.

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.